Changjiang Runfa Health Industry Co., Ltd.

As of March 31, 2024, Changjiang Runfa Health Industry Co., Ltd. has 1.24B shares outstanding.

As of March 31, 2024, Changjiang Runfa Health Industry Co., Ltd. trades at a trailing price-to-earnings ratio of 88.44. The price-to-sales ratio is 1.29, and the price-to-book ratio stands at 10.69.

These figures are as of March 31, 2024. The EV/Sales ratio of 1.79 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Changjiang Runfa Health Industry Co., Ltd. trades at an EV/FCF ratio of 18.44, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of March 31, 2024, Changjiang Runfa Health Industry Co., Ltd. maintains a current ratio of 1.25, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 60.84, indicating elevated leverage, while an interest coverage ratio of -0.96 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2024, Changjiang Runfa Health Industry Co., Ltd. posted a negative return on equity (ROE) of -106.74, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -10.25, reflecting losses generated across the asset base. Return on capital employed (ROCE) is 2.44, useful for judging operating efficiency across full business cycles. Inventory turnover of 3.73 indicates how many times Changjiang Runfa Health Industry Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

These figures cover the twelve months ended March 31, 2024. That works out to an effective tax rate of 47.44, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

As of the close on July 1, 2024, Changjiang Runfa Health Industry Co., Ltd.'s stock has declined approximately 92.40% over the past 52 weeks. The 50-day moving average sits at 1.48, while the 200-day moving average is 3.37.

Over the twelve months ended March 31, 2024, Changjiang Runfa Health Industry Co., Ltd. posted a gross margin of 29.79, reflecting its pricing power and cost economics. The operating margin of -2.94 and net profit margin of -27.67 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2024. The dividend payout ratio of -26.49 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 5.09, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -4.72, meaning Changjiang Runfa Health Industry Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Changjiang Runfa Health Industry Co., Ltd.'s most recent stock split took place on June 18, 2019 with a 2:3 split ratio.

As of March 31, 2024, Changjiang Runfa Health Industry Co., Ltd. has an Altman Z-Score of 0.85, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.